Journal: Scientific Reports

Article Title: Networked lymphatic endothelial cells in a transplanted cell sheet contribute to form functional lymphatic vessels

doi: 10.1038/s41598-022-26041-0

Figure Lengend Snippet: Secretion of growth factors by adipose-derived stem cells (ASCs) and the formation of networks by co-culture with endothelial cells (ECs) or lymphatic endothelial cells (LECs). ( a ) The levels of vascular endothelial growth factor-C (VEGF-C), VEGF-A, hepatocyte growth factor (HGF) and basic fibroblast growth factor (bFGF) in the medium bathing cultured ASCs were measured using enzyme-linked immunosorbent assays. HGF and VEGF-A were both secreted by ASCs, whereas the levels of secreted VEGF-C and b-FGF were much lower. ( b ) Green fluorescent protein (GFP)-expressing ECs and ASCs co-cultured at a ratio of 1:4. Networks of vascular ECs were observed, and the edges of the vascular EC network were sharp (arrows). ( c ) GFP-LECs and ASCs co-cultured at a ratio of 1:4. The LECs formed networks, but in contrast to vascular ECs, rounded/bulging structures were observed at the edges of the LEC network (arrowheads). ( d ) Merge image of ( c ) and phase-contrast image. ASCs shows random pattern with no specific character which do not form own network or support LEC network directly.

Article Snippet: The concentrations of VEGF-C, VEGF-A, HGF, and bFGF were measured by enzyme-linked immunosorbent assay (ELISA) using a Human VEGF-C ELISA Kit (P49767, RayBiotech, USA), LBIS Human VEGF ELISA Kit (631-40831, Fujifilm Wako, Japan), AuthentiKine Human HGF ELISA Kit (KE00168, Proteintech, USA) and Human bFGF ELISA Kit (P09038, RayBiotech, USA) in accordance with the manufacturers’ instructions.

Techniques: Derivative Assay, Co-Culture Assay, Cell Culture, Expressing

Journal: International Journal of Biological Sciences

Article Title: N 6 -methyladenosine Reader IGF2BP2-modified HMMR Promotes Non-small Cell Lung Cancer Metastasis via Interaction with MAP4K4

doi: 10.7150/ijbs.104097

Figure Lengend Snippet: MAP4K4 inhibitor GNE-495 reduces NSCLC cell metastasis in vivo . (A) Flowchart illustrating the NSCLC cell in vivo metastasis model. (B) Relative mRNA and protein expression levels of HMMR and MMP1 in the A549 cells used to establish the in vivo metastasis model. (C) Photographs showing lung metastatic nodules in mice following injection of A549 cells overexpressing HMMR or the control vector, with treatment by DMSO or GNE-495. Metastatic nodules are indicated by red arrowheads. (D) Quantification of lung metastatic nodules across the four experimental groups. (E) The lung weights of the mice in each group after execution. (F) Hematoxylin and eosin (H&E) staining of lung tissue to assess micrometastatic foci. Representative histological images of micrometastatic foci in the four groups. Micrometastatic foci are indicated by blue arrowheads.

Article Snippet: From the fifth week post-injection, mice received daily intraperitoneal injections of either DMSO (3 mg/kg) or the MAP4K4 inhibitor GNE-495 (HY-100343, MCE, China) (3 mg/kg).

Techniques: In Vivo, Expressing, Injection, Control, Plasmid Preparation, Staining

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Flow cytometry antibodies used.

Article Snippet: CD3-VB , Miltenyi , 130-133-133 , BW264/56 , .

Techniques: Flow Cytometry, In Vivo, In Vitro

Journal: Cancers

Article Title: Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

doi: 10.3390/cancers13081845

Figure Lengend Snippet: Murlentamab opsonization of SKOV3-R2 + activates an effective anti-tumor T cell immune response. SKOV3-R2 + ovarian tumor cells were labeled with different 3C23K antibodies (3C23K-FcKO control, 3C23K-CHO normally fucosylated or murlentamab the low fucosylated form) and cultured in the presence of human monocyte-derived macrophages from healthy donors unstimulated (M0) or stimulated with M-CSF and IL-10 (TAMs). After 3 days of co-culture, activated T cells coming from the same healthy donor were added in the culture well for 4 more days. ( A ) The CD4 + Th1/Th2 polarization profile, ( B ) the proportion of CD3 + CD4 + CD25 + regulatory T cells and ( C ) the activation of T CD8 + cells were determined by flow cytometry after four days of co-culture. Data shown (boxplots) are the results from two different experiments (performed with two different healthy donors). * p < 0.05; ** p < 0.01; *** p < 0.001. p values were determined using one-way ANOVA analysis followed by Tukey’s multiple comparisons test.

Article Snippet: CD3-VB , Miltenyi , 130-133-133 , BW264/56 , .

Techniques: Labeling, Cell Culture, Derivative Assay, Co-Culture Assay, Activation Assay, Flow Cytometry

Journal: Antioxidants

Article Title: Correlations between Salivary Immuno-Biochemical Markers and HbA1c in Type 2 Diabetes Subjects before and after Dental Extraction

doi: 10.3390/antiox10111741

Figure Lengend Snippet: Pre- and post-extraction OPG, RANKL, HGF, TNF-α, IL-18, MMP-9, TOS—total oxidant status, TAC—total antioxidant capacity, and HbA1c values in control and diabetes mellitus patients.

Article Snippet: A number of parameters were determined in saliva, using the ELISA immunenzymatic method: OPG (MyBioSource, San Diego, CA, United States, # MBS175881), RANKL (MyBioSource, San Diego, CA, United States, # MBS268235), HGF (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0084), TNF-α (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0109), MMP-9 (Abcam, CA, United Kingdom, ab246539), IL-18 (Abcam, Cambridge, United Kingdom, ab215539), and the spectrophotometric method determined TAC (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey) and TOS (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey), according to the method described by Erel in 2005 [ ].

Techniques: Control

Journal: Antioxidants

Article Title: Correlations between Salivary Immuno-Biochemical Markers and HbA1c in Type 2 Diabetes Subjects before and after Dental Extraction

doi: 10.3390/antiox10111741

Figure Lengend Snippet: ROC curve. Prediction of salivary markers in the determinism of HbA1c > 6.5%.

Article Snippet: A number of parameters were determined in saliva, using the ELISA immunenzymatic method: OPG (MyBioSource, San Diego, CA, United States, # MBS175881), RANKL (MyBioSource, San Diego, CA, United States, # MBS268235), HGF (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0084), TNF-α (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0109), MMP-9 (Abcam, CA, United Kingdom, ab246539), IL-18 (Abcam, Cambridge, United Kingdom, ab215539), and the spectrophotometric method determined TAC (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey) and TOS (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey), according to the method described by Erel in 2005 [ ].

Techniques:

Journal: Antioxidants

Article Title: Correlations between Salivary Immuno-Biochemical Markers and HbA1c in Type 2 Diabetes Subjects before and after Dental Extraction

doi: 10.3390/antiox10111741

Figure Lengend Snippet: Post-extraction correlation of HbA1c with salivary markers (OPG, RANKL, OPG/RANKL, HGF, TNF-α, MMP-9, IL-18, TOS and TAC).

Article Snippet: A number of parameters were determined in saliva, using the ELISA immunenzymatic method: OPG (MyBioSource, San Diego, CA, United States, # MBS175881), RANKL (MyBioSource, San Diego, CA, United States, # MBS268235), HGF (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0084), TNF-α (Elabscience, Houston, Texas, United States, Catalog no. E-EL-H0109), MMP-9 (Abcam, CA, United Kingdom, ab246539), IL-18 (Abcam, Cambridge, United Kingdom, ab215539), and the spectrophotometric method determined TAC (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey) and TOS (Rel Assay Diagnostics Kit, Mega Tıp, Gaziantep, Turkey), according to the method described by Erel in 2005 [ ].

Techniques: Extraction

Journal: MedComm

Article Title: Low‐dose exercise protects the heart against established myocardial infarction via IGF‐1‐upregulated CTRP9 in male mice

doi: 10.1002/mco2.411

Figure Lengend Snippet: Low‐dose exercise upregulates cardiac C1q complement/tumor necrosis factor‐associated protein 9 (CTRP9) expression by increasing circulating insulin‐like growth factor 1 (IGF‐1). (A) Isolated cardiomyocytes were treated with serum samples from myocardial infarction (MI) mice with different doses of exercise intervention. (B) CTRP9 expression level in cardiomyocytes after treatment with serum from MI mice ( n = 4) for quantitative real‐time polymerase chain reaction (qPCR) and n = 3 for western blotting. (C) Heatmap of serum proteomics of MI mice with low‐dose exercise ( n = 3). (D) CTRP9 expression level in cardiomyocytes after treatment with IGF‐1 or hyaluronan binding protein 2 (HABP2) ( n = 4). (E) Concentration of circulating IGF‐1 in MI mice post‐exercise ( n = 6). (F) Concentration of circulating IGF‐1 in cardiac‐specific knockdown of CTRP9 mice post‐exercise ( n = 6). (G) Concentration of circulating IGF‐1 in cardiac‐specific CTRP9 overexpression mice ( n = 6). (H) Protocol for IGF‐1 supplementation in CTRP9 knockout (KO) mice with established MI. IGF‐1 was administered via intraperitoneal injection 4 weeks post‐surgery. (I) CTRP9 expression level in CTRP9 KO mice heart post‐exercise ( n = 4). (J) Concentration of circulating IGF‐1 in CTRP9 KO mice after administration of IGF‐1 ( n = 6). (K) Supplementation of IGF‐1 failed to improve cardiac function in CTRP9 KO mice ( n = 8). (L and M) Cardiac infarct size (L) ( n = 6) and heart weight to body weight ratio (M) ( n = 8) in CTRP9 KO mice with IGF‐1 treatment. (N and O) Cardiac wheat germ agglutinin (WGA) staining (N) ( n = 6) and Masson staining (O) ( n = 6) in CTRP9 KO mice with IGF‐1 treatment. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: Depending on the experimental grouping, IGF‐1 (50437, Sino Biological Inc.) or HABP2 (HY‐P70832, MedChemExpress LLC) was added 24 h before the end of the culture.

Techniques: Expressing, Isolation, Real-time Polymerase Chain Reaction, Western Blot, Binding Assay, Concentration Assay, Over Expression, Knock-Out, Injection, Staining